Background: As a regulator of transcription via chromatin remodeling, p300 is a histone acetyltransferase that binds to adenovirus E1A protein and may play a role in its transforming capacity. EID-2 (EP300-interacting inhibitor of differentiation 2), also known as CREBBP/EP300 inhibitor 2, is a 236 amino acid nuclear protein that cooperates with EID-2B to bind to the C-terminus of p300 to inhibit its activity. It also represses MYOD-dependent transcription and muscle differentiation. By interacting with SMAD2, SMAD3 and SMAD4, EID-2 selectively blocks the formation of TGFB-induced SMAD3-SMAD4 complex, thereby repressing TGFB/SMAD3-dependent signaling. Though it is abundantly expressed in placenta, EID-2 is highly expressed in skeletal muscle, heart, liver, brain and kidney. There are two isoforms of EID-2 that are produced as a result of alternative splicing events.
Description: Rabbit polyclonal to EID2
Immunogen: KLH conjugated synthetic peptide derived from EID2
Specificity: ·Reacts with Human, Mouse and Rat.
.·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 25 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
